文献速递白血病

光学基因组图谱在急性髓系白血病中的多中心评估

Optical genome mapping in acute myeloid leukemia: a multicenter evaluation.
PubMed 文献 · Blood Adv · 2023-01-01

该多中心研究在100例急性髓系白血病(AML)病例中评估光学基因组图谱(OGM)的性能,这些病例此前已通过核型分析或核型联合FISH或CMA进行表征。OGM识别了标准方法报告的所有临床相关结构变异和拷贝数变异(当代表性克隆等位基因分数>5%时),并在13%的病例中发现了常规方法遗漏的临床相关信息。

要点

  • OGM在代表性克隆等位基因分数>5%时,识别了标准细胞遗传学方法报告的所有临床相关结构变异和拷贝数变异。
  • OGM在13%的病例中发现了常规方法遗漏的临床相关信息,其中3例核型正常者存在涉及基因融合的隐匿性易位。
  • 在4%的病例中OGM结果会改变推荐的临床管理,另有8%的病例可能因OGM结果而符合临床试验条件。

核心结论

  • 这项多机构研究表明,OGM有效回收了标准诊疗方法发现的结构变异和拷贝数变异,并揭示了未报告的额外结构变异。
  • OGM减少了对劳动密集型多次细胞遗传学检测的需求,同时通过标准化工作流程最大化诊断检出。

研究设计与样本

  • 多中心评估,纳入100例先前仅用核型分析或核型联合FISH或CMA表征的AML病例,在真实世界环境中评估OGM性能。

主要发现

  • 当代表性克隆等位基因分数>5%时,OGM识别了标准细胞遗传学方法报告的所有临床相关结构变异和拷贝数变异。
  • OGM在13%的病例中识别了常规方法遗漏的临床相关信息。
  • 3例报告核型正常的病例被显示存在涉及基因融合的隐匿性易位。
  • 在4%的病例中,OGM结果会改变推荐的临床管理;另有8%的病例,OGM会使病例可能符合临床试验条件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Detection of hallmark genomic aberrations in acute myeloid leukemia (AML) is essential for diagnostic subtyping, prognosis, and patient management. However, cytogenetic/cytogenomic techniques used to identify those aberrations, such as karyotyping, fluorescence in situ hybridization (FISH), or chromosomal microarray analysis (CMA), are limited by the need for skilled personnel as well as significant time, cost, and labor. Optical genome mapping (OGM) provides a single, cost-effective assay with a significantly higher resolution than karyotyping and with a comprehensive genome-wide analysis comparable with CMA and the added unique ability to detect balanced structural variants (SVs). Here, we report in a real-world setting the performance of OGM in a cohort of 100 AML cases that were previously characterized by karyotype alone or karyotype and FISH or CMA. OGM identified all clinically relevant SVs and copy number variants (CNVs) reported by these standard cytogenetic methods when representative clones were present in >5% allelic fraction. Importantly, OGM identified clinically relevant information in 13% of cases that had been missed by the routine methods. Three cases reported with normal karyotypes were shown to have cryptic translocations involving gene fusions. In 4% of cases, OGM findings would have altered recommended clinical management, and in an additional 8% of cases, OGM would have rendered the cases potentially eligible for clinical trials. The results from this multi-institutional study indicate that OGM effectively recovers clinically relevant SVs and CNVs found by standard-of-care methods and reveals additional SVs that are not reported. Furthermore, OGM minimizes the need for labor-intensive multiple cytogenetic tests while concomitantly maximizing diagnostic detection through a standardized workflow.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Levy B, Baughn LB, Akkari Y, et al. Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Adv. 2023. PMID: 36417763. doi:10.1182/bloodadvances.2022007583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。